@article{50e3d0a285c748eb844e640f8f93c63e,
title = "5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials",
author = "Reddy, \{Vivek Y.\} and Doshi, \{Shephal K.\} and Saibal Kar and Gibson, \{Douglas N.\} and Price, \{Matthew J.\} and Kenneth Huber and Horton, \{Rodney P.\} and Maurice Buchbinder and Petr Neuzil and Gordon, \{Nicole T.\} and Holmes, \{David R.\} and Investigators, \{Protect Af\}",
note = "Background The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) trial demonstrated that left atrial appendage closure (LAAC) with the Watchman device (Boston Scientific, St. Paul, Minnesota) was equivalent to warfarin for preventing stroke in atrial fibrillation, but had a high rate of complications.",
year = "2017",
month = dec,
day = "19",
doi = "10.1016/J.JACC.2017.10.021",
language = "American English",
volume = "70",
journal = "Journal of the American College of Cardiology",
number = "24",
}